Age: <1 Year
Vaccine
Age of 1st Dose
Doses in Primary (min interval
between doses)
Booster
Comments
CORE VACCINES
Infectious canine
hepatitis (canine
adenovirus)
6-18
weeks
2 doses, 3-4 weeks apart
After 1-yr and then every 3-yr
Included in DAPPV
ADDITIONAL VACCINES
Parenteral
/ oral: >8
weeks
Nasal: >3
weeks
Parenteral: 2 doses,
2-4 weeks apart
Nasal/oral: 1 dose
1 year
Lifestyle vaccine
(boarding/showing)
>9 weeks
2 doses, 3-4 weeks apart
Annual prior to the start of tick season
Only for high-risk areas
>8 weeks
2 doses, 3-4 weeks apart
Once yearly for dogs in high-risk areas
Vaccine is recommended for all dogs as all dogs are at-risk
VISIT # 1
6-9 WEEKS; FULL TEAM
Service Provided
Product Info
DA2PP + Leptospirosis vaccine combo
ULTRA DURAMUNE DAP PLUS 4L (Elanco; SQ)
VANGUARD DAPP/L4 (Zoetis; SQ)
NOBIVAC CANINE 1-DAPPV PLUS L4 (Merck; SQ)
IDEXX Fecal Dx® Profile with Giardia (24639)
Drontal Plus
Simparica Trio Chewable Tablets*
1 dose
Microchip placement
Pet Link
Add-ons
Nail Trim
Forti Flora SA Canine Probiotic Supplement
VISIT # 2
10-13 WEEKS; TECH DRIVEN
Service Provided
Product Info
DA2PP + Leptospirosis vaccine combo
Same brand as prime
Bordetella + Parainfluenza vaccine
Oral
NOBIVAC Intra-Trac Oral BbPi (Merck)
Bordetella + Parainfluenza vaccine
Intranasal
VANGUARD® RAPID RESP 3 (Zoetis)
NOBIVAC INTRA-TRAC3 (Merck)
BRONCHI-SHIELD III (Elanco)
Recombitek KC2 Vaccine (BI)
Drontal Plus
Simparica Trio Chewable Tablets
1 dose
Add-ons
Nail Trim
VISIT # 3
14-17 WEEKS; FULL TEAM
Service Provided
Product Info
DA2PP + Leptospirosis vaccine combo
Same brand as prime
Rabies 1-year vaccine
IMRAB 1 (BI)
RABVAC 1 RABIES VACCINE (Elanco)
NOBIVAC RABIES 1 (Merck)
VANGUARD RABIES 1 (Zoetis)
IDEXX Fecal Dx® Profile with Giardia (24639)
Drontal Plus
Simparica Trio Chewable Tablets
1 dose*
Add-ons
Bivalent flu vaccine
VANGUARD CIV H3N2 H3N8 (Zoetis)
NOBIVAC CIV CANINE FLU BIVALENT (Merck)
Lyme vaccine
NOBIVAC LYME (Merck)
DURAMUNE LYME VACCINE (Elanco)
RECOMBITEK LYME (BI)
Nail Trim
Forti Flora SA Canine Probiotic Supplement
● DA2PP + Leptospirosis vaccine combo: Puppies under 12 weeks of age should be
revaccinated every 3 to 4 weeks, and the last dose given at or over 16 weeks of age.
● *Home visit schedule change: If lyme and flu vaccines are unnecessary - provide 3 Simparica Trio doses, add anal gland expression and skip Visit #4.
VISIT # 4**
18-21 WEEKS; TECH-DRIVEN
Service Provided
Product Info
Simparica Trio Chewable Tablets
3 doses
Add-ons
Anal gland expression
As needed
Lyme vaccine
Same brand as prime
Bivalent flu vaccine
Same brand as prime
Nail trim
** Only when influenza and lyme vaccines are administered.
VISIT # 5
7 Months or older; TECH-DRIVEN
Service Provided
Product Info
IDEXX Young Wellness with Lab 4Dx® Plus Test (Canine) (26059999)
Chem 10 with IDEXX SDMA® Test, IDEXX CBC®, Lab 4Dx® Plus Test
IDEXX Fecal Ova and Parasites (501)
Simparica Trio Chewable Tablets
6 doses
Dental chews
CET
Add-ons
Nail Trim
Prevention is without a doubt the most efficient, cost-effective therapy. Screening and early detection are crucial to minimize morbidity and future healthcare costs. Therefore, comprehensive testing is strongly recommended as a screening tool. See table below for recommended tests by The Vets Internal Medicine expert, Dr. Andrea Johnston.
Test Name
Info
Price
TIER 1
Wellness with Lab 4Dx® Plus Test (Canine) (26059999)
Chem 10 with IDEXX SDMA® Test, IDEXX CBC®, Lab 4Dx® Plus Test
$159.39
IDEXX Fecal Ova and Parasites (501)
$46.80
TIER 2
IDEXX Young Wellness
(28079999)
Chem 10 with IDEXX SDMA® Test, IDEXX CBC®
$97.90
IDEXX Heartworm Antigen by ELISA Add-on - Canine (7231)
$34.78
IDEXX Fecal Ova and Parasites (501)
$46.80
TIER 3
IDEXX Young Preanesthetic
Profile (7839999)
Alkaline phosphatase, ALT (SGPT), BUN, creatinine, glucose, IDEXX SDMA® Test, total protein, IDEXX CBC®
$105.98
IDEXX Heartworm Antigen by ELISA Add-on - Canine (7231)
$34.78
IDEXX Fecal Ova and Parasites (501)
$46.80
https://www.aspca.org/pet-care/animal-poison-control
The AVMA and AAHA discourage the feeding of raw animal-source protein due to the high risk of illness to both pets and humans. Pathogens found in raw protein diets can be transmitted to the human population by contact with the food, pet, or environmental surfaces.
Neutering is associated with a prolonged life expectancy for both sexes compared to their entire
counterparts. This has been reported in multiple studies. In female dogs, neutering reduces or
eliminates the risk of pyometra, a potentially life-threatening condition. Neutering is linked to a
reduced risk of cancer of reproductive organs and heart disease, but an increased risk of joint
disorders and some cancers (lymphoma and hemangiosarcoma) especially in females. [1,2]
Health risks by breed can be found at https://www.akc.org/ under the Health link on each breed information page. A handful of larges cale publications on breed related mortality are available.
Brachycephalic breeds (French Bulldog, English Bulldog, Pug, and American Bulldog) are predispositions to life-limiting disorders that occur early in life, such as brachycephalic obstructive airway syndrome (BUAS), spinal disease, and dystocia.
Brachycephalic breeds should avoid high temperatures, overexertion, and over-conditioning (obesity). Harnesses rather than collars should be used for leash walks. Pre-emptive surgical intervention to improve upper airway conformation should be recommended before a respiratory crisis occurs.
Deep chested, large breed dogs (Great Danes, Weimaraners, St. Bernards, Irish setters, Gordon
setters...) are predisposed gastric dilation volvulus (GDV). Pre-emptive gastropexy should be
recommended to reduce the GDV. Feed more than one meal a day and select a dog food with a
low fat and oil content.
Chondrodystrophic breeds (Dachshund, Pekinese, Beagle, Lhasa Apso) are pre-disposed to
intervertebral disk disease (IVDD). Avoid over-feeding and obesity. Use a harness rather than a
collar for leash walks. Avoid high impact activities like jumping on and off furniture, consider the
use of portable pet stairs.
Many breeds are predisposed to congenital heart disease. If a murmur or arrhythmia is
detected on annual physical exam, a thoracic radiograph or EKG should be pursued. If these are
abnormal, a cardiology referral is recommended. [6, open access journal with helpful diagnostic
flow chart]
Vaccination is an efficient and cost-effective form of infectious disease prevention. Most current vaccines are delivered by injection, which provide systemic protection but partial to no protection at mucosal sites. Considering that >90% of pathogens gain access to the body via mucosal sites, using mucosal vaccination to generate protective immunity at mucosal sites could over-come the limitations of current injection-based vaccines in providing front-line protection against pathogen invasion and dissemination (Holmgren J., Czerkinsky C., 2005; Gerdts V. et al.,2006).
Mucosal tissues (e.g. nasal, oral, ocular, rectal, vaginal) cover a large surface of the body. Since many infections are initiated at mucosal sites, it is critical to develop strategies for neutralising the infectious agent at these surfaces. Mucosal vaccination involves the administration of vaccines at one or more mucosal sites leading to induction of immune responses at the mucosal site of administration, other mucosal sites, and/or systemically.
Immunization involves the delivery of antigens to the mucosal immune system (into
units such as Peyer’s patches in the intestine or the nasal-associated lymphoid tissue in the oropharyngeal cavity). The effector mechanisms for mucosal immune response include the hallmark secretory Immunoglobulin A (SIgA), a protease-resistant antibody and the cell-mediated mucosal immune response. These effectors have been shown to be effective for the clearance of various pathogens including enteric/respiratory viruses and intracellular parasites.
IgA is the first line of defense in the resistance against infection, via inhibiting bacterial and viral adhesion to epithelial cells and by neutralization of bacterial toxins and virus, both extra- and intracellularly. IgA also eliminates pathogens or antigens via an IgA-mediated excretory pathway where binding to IgA is followed by polyimmunoglobulin receptor-mediated transport of immune complexes. SIgA has an important role in mediating the adaptive (antigen specific) humoral (antibody-based) immune defense at mucosal surfaces.
The majority of mucosal vaccines are administered by the oral and nasal routes.
However, not all routes of administration induce an equivalent immune response in terms of potency and longevity, reflecting differences in the organization and cellular make-up of lymphoid structures in different mucosal tissues (Kantele A., et al., 1998; Czerkinsky C., et al., 2012; Czerkinsky C., Holmgren J., 2010).
For example, oral immunization usually stimulates immune responses in the GI tract in
addition to the oral mucosa and nasal-associated lymphoid tissues (NALT) and mammary glands. Intranasal delivery effectively induces antibody production in salivary glands, the NALT and the bronchus-associated lymphoid tissue (BALT) of the lower respiratory tract, and in the urogenital tract. Rectal immunization elicits a more pronounced immune and antibody response in nasal secretions, tears and the rectal mucosa. Thus, depending on the mucosal sites targeted by different pathogens, the route of immunization needs to be care-fully considered (Fujkuyama Y., et al., 2012; Czerkinsky C., Holmgren J., 2010; Saroja C., et al., 2011).
1. Teng K.T., Brodbelt D.C., Pegram C., Church D.B., O'Neill D.G. Life tables of annual life expectancy and
mortality for companion dogs in the United Kingdom. Sci Rep. 2022 Apr 28;12(1):6415. doi:
10.1038/s41598-022-10341-6. PMID: 35484374; PMCID: PMC9050668.
2. Urfer, S. R. & Kaeberlein, M. Desexing dogs: A review of the current literature. Animals 9, 1086 (2019).
42.
3. Hart, L. A. & Hart, B. L. An ancient practice but a new paradigm: Personal choice for the age to spay or
neuter a dog. Front. Vet. Sci. 8, 244 (2021).
4. O’Neill, D. G., Church, D. B., McGreevy, P. D., Tomson, P. C. & Brodbelt, D. C. Longevity and mortality of
owned dogs in England. Vet. J. 198, 638–643 (2013).
5. Brambilla P.G., Polli M., Pradelli D., Papa M., Rizzi R., Bagardi M., Bussadori C. Epidemiological study of
congenital heart diseases in dogs: Prevalence, popularity, and volatility throughout twenty years of
clinical practice. PLoS One. 2020 Jul 27;15(7):e0230160. doi: 10.1371/journal.pone.0230160. PMID:
32716943; PMCID: PMC7384636.
6. Saunders AB. Key considerations in the approach to congenital heart disease in dogs and cats. J Small
Anim Pract. 2021 Aug;62(8):613-623. doi: 10.1111/jsap.13360. Epub 2021 Jun 27. PMID: 34180062.
A. Miquel-Clopés et al., Mucosal Vaccines and Technology, Clinical & Experimental Immunology
2019
Mucosal Veterinary Vaccines: Comparative Vaccinology
USDA Approved Animal Rabies Vaccines
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114856/
https://wsava.org/wp-content/uploads/2020/01/WSAVA-Vaccination-Guidelines-2015.pdf
https://www.aaha.org/globalassets/02-guidelines/canine-vaccination/vaccination_recommend
ation_for_general_practice_table.pdf
https://onlinelibrary.wiley.com/doi/10.1111/jsap.2_12431
https://www.maine.gov/dhhs/mecdc/infectious-disease/epi/zoonotic/rabies/documents/2017-
Maine-Rabies-Management-Guidelines-4th-edition.pdf
https://www.aaha.org/aaha-guidelines/vaccination-canine-configuration/vaccination-recomme
ndations-for-general-practice/
https://pets.webmd.com/pet-vaccines-schedules-cats-dogs